Infliximab 10 mg/kg ( DrugBank: Infliximab )

3 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	1
96	Crohn disease	2
97	Ulcerative colitis	1

46. Malignant rheumatoid arthritis

Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00269867 (ClinicalTrials.gov)	March 1997	22/12/2005	Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis	A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment	Rheumatoid Arthritis	Drug: Placebo;Drug: Infliximab 3 mg/kg;Drug: Infliximab 10 mg/kg	Centocor, Inc.	NULL	Completed	18 Years	75 Years	Both	428	Phase 3	NULL

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00269841 (ClinicalTrials.gov)	May 1996	22/12/2005	An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease	A Placebo-Controlled, Repeated-Dose Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease	Crohn Disease	Drug: Infliximab 10 mg/kg;Drug: Infliximab 5 mg/kg;Drug: Placebo	Centocor, Inc.	NULL	Completed	18 Years	65 Years	Both	94	Phase 3	NULL
2	NCT00269854 (ClinicalTrials.gov)	June 1995	22/12/2005	An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease	A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease	Crohn Disease	Drug: Infliximab 5 mg/kg;Drug: Infliximab 10 mg/kg;Drug: Infliximab 20 mg/kg;Drug: Placebo	Centocor, Inc.	NULL	Completed	18 Years	65 Years	Both	108	Phase 2/Phase 3	NULL

Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00207688 (ClinicalTrials.gov)	August 31, 2004	13/9/2005	A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients	A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis	Ulcerative Colitis	Drug: Infliximab 5 mg/kg;Drug: Infliximab 10 mg/kg;Drug: Placebo	Janssen Research & Development, LLC	Janssen Biologics BV	Completed	N/A	N/A	All	505		New Zealand;Switzerland;United Kingdom;Argentina;Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Israel;Netherlands;United States;Czech Republic